Mauna Kea touts Cellvizio pancreatic cyst diagnosis data

Mauna Kea (ENT:MKEA) today touted the results from a recently published study of its Cellvizio system which supported the use of the device in diagnosing pancreatic cysts. The Cellvizio device is designed for use in a variety of surgical procedures, providing real time visualization at the microscopic level, Mauna Kea said. Results from the study were published in the World Journal of Gastroenterology, the French company said. In the study, researchers evaluated in vivo and ex vivo confocal endomicroscopy of pancreatic cystic lesions, Mauna Kea reported. The researchers concluded that in vivo nCLE patterns were reproducible in ex vivo pCLE for all major neoplastic pancreatic cysts. “This new peer reviewed study led by Dr. Krishna provides further validation of the application of Cellvizio needle-based CLE in the diagnosis of pancreatic cysts. There is a significant opportunity for clinicians to use optical biopsy with Cellvizio in the often-challenging task of diagnosing pancreatic cysts, allowing them to make faster diagnoses and better treatment decisions to achieve better outcomes for their patients,” CEO Sacha Loiseau said in a prepared release. In May, Mauna Kea touted data from a study examining the use of its Cellvizio platform in assessing acute lung rejection following transplant. Results from follow-up exams of 24 lung transplant patients were used in the study, with CLE video-imaging obtained prior to tissue sampling, Mauna Kea said. Endomicroscopy...
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Imaging Mauna Kea Technologies Source Type: news

Related Links:

Conclusion Several TISC-based immunotherapeutic approaches are under development in various stages of preclinical studies. As outlined in this review article, a careful and more exhaustive genetic and metabolic understanding of TISC-associated phenotypes is critical to develop novel TISC based immunotherapies. Various components within the tumor microenvironment such as tumor cells, infiltrating immune cells, and supporting stromal cells impact the TISC metabolism. This unique metabolic profile leads to upregulation of certain enzymes and proteins such as ALDH1, CEP55, IDO COA1 etc., which can be utilized for development ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractPrimary graft dysfunction (PGD) remains the leading cause of early mortality post-heart transplantation. Despite improvements in mechanical circulatory support and critical care measures, the rate of PGD remains significant. A recent consensus statement by the International Society of Heart and Lung Transplantation (ISHLT) has formulated a definition for PGD. Five years on, we look at current concepts and future directions of PGD in the current era of transplantation.
Source: Heart Failure Reviews - Category: Cardiology Source Type: research
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Source Type: research
Long-term survival after lung transplantation remains limited by the development of chronic lung allograft dysfunction (CLAD), which affects approximately 50% of lung recipients by 5 years post-transplant.1 Given the lack of a proven therapy once CLAD is diagnosed, risk factor mitigation is a key preventive strategy. The principal risk factor for CLAD is A-grade acute cellular rejection (ACR). A-grade ACR is diagnosed by transbronchial biopsy (TBB), exhibiting perivascular mononuclear cell infiltrates that extend into the interstitium with higher grade rejection.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: EDITORIAL Source Type: research
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Source Type: research
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Source Type: research
A Nova Scotia woman has received a double lung transplant just months after she thought the financial burden of the procedure would force her into palliative care.
Source: CBC | Health - Category: Consumer Health News Tags: News/Canada/Nova Scotia Source Type: news
CONCLUSION: These new recommendations, close to French practices, help clinicians to find the right time for referral of patients to transplantation centers. This is crucial for the prognosis of lung transplantation. PMID: 31006579 [PubMed - as supplied by publisher]
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
Geng-Hong Xia1†, Chao You1,2†, Xu-Xuan Gao1, Xiu-Li Zeng1, Jia-Jia Zhu1, Kai-Yu Xu3, Chu-Hong Tan1, Ruo-Ting Xu1, Qi-Heng Wu1, Hong-Wei Zhou3, Yan He4*‡ and Jia Yin1*‡ 1Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, China 2Department of Neurology, The First People's Hospital of Zunyi, Zunyi, China 3State Key Laboratory of Organ Failure Research, Division of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China 4Microbiome Medicine Center, Division of Laboratory Medicine, Zhujiang Hospital, Southern Medical Univ...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Conclusions: Our results show worldwide efficacy of BM-MSCs in improving functional outcomes in pre-clinical animal models of stroke and support testing these cells in clinical trials in various ranges of time windows using different delivery routes. The continued growing number of publications showing functional benefit of BM-MSCs are now adding limited value to an oversaturated literature spanning 18 years. Researchers should focus on identifying definitive mechanisms on how BM-MSCs lead to benefit in stroke models. Introduction Ischemic stroke is the 5th leading cause of death and the leading cause of long term di...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
More News: Clinical Trials | France Health | Gastroenterology | Lung Transplant | Pancreas | Study | Transplant Surgery | Transplants